News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

News

Webcast

Webcasts

August 14, 2024

Advancing Validation: 2024 Insights and Trends

Author(s):

Kneat

Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT

The future of validation is here! The State of Validation is the only annual research report dedicated to the validation industry. Join this webinar to dive deep into the findings with validation industry experts who will offer their unique perspectives on the implications and opportunities revealed in the report.

Register Free: https://www.pharmexec.com/pe_w/advancing-validation

Event Overview:

Explore the latest pharmaceutical validation developments during this panel discussion with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape. Attend to learn:

  • Industry Evolution: Explore key opportunities and emerging trends in the validation industry today, including the adoption of digital validation, the integration of Industry/Pharma 4.0 technologies, and the increasing shift towards remote regulatory assessments.
  • Adaptation Strategies: Gain insights into how organizations of varying sizes and sectors are adapting to new validation paradigms and what this means for the pharma industry.
  • Future Directions: Hear expert opinions on the strategic directions validation practices are taking, focusing on technological advancements and efficiency improvements.
  • Solving Challenges: Learn about approaches to overcoming common 2024 validation challenges, such as compliance burden and audit readiness, illustrated through real-world applications.

Key Learning Objectives:

  • Identifying Future Challenges: Gain a deep understanding of the key challenges validation teams are likely to face in the coming years. This includes preparing for evolving regulatory requirements, managing increasing workloads, and integrating new technologies into existing validation practices.
  • Recognizing Emerging Priorities: Learn to identify and prioritize emerging trends within the pharma validation industry, such as the growing emphasis on data integrity and remote auditing. You’ll be equipped to align strategies with these priorities to enhance your validation work and maintain compliance.
  • Staying Ahead With Industry Trends: Acquire knowledge on the latest validation industry trends, including the adoption of digital validation systems and the shift toward Pharma 4.0. By understanding these trends, you can proactively adapt your strategies to stay competitive and efficient.

Who Should Attend:
This webinar is a must-attend for validation, quality assurance, and compliance professionals seeking to understand the evolving landscape of their field, gain insights from leading experts, and discover how to leverage these changes for better compliance and enhanced efficiency in their organizations.

Speakers:


Art Gehring
Vice President, Marketing
Kneat Solutions

As vice president of marketing at Kneat Solutions, Art Gehring leads a global team of world class marketers educating the industry on the benefits of digital validation. Prior to joining Kneat in 2023, Gehring was a marketing executive and QMS software leader ETQ, helping organizations enhance and automate manual quality processes. Gehring’s tenure also includes leadership roles at Lotus/IBM, Brainshark, ATG, and Virgin Pulse. He holds an MBA in marketing and BS in economics. Gehring and his family of 5 live in Lexington, Massachusetts.

Adolfo Santana
Partner, Quality and Regulatory Compliance Consulting Services
Barry-Wehmiller Design Group

Adolfo Santana is a life sciences partner in the regulatory compliance practice, with over 30 years of experience in pharmaceutical product technical development, scale up, and commercialization, quality systems design and implementation, and regulatory inspection preparation and compliance remediation. He is a subject matter expert in all stages of process validation and commissioning, qualification, and validation of facilities, utilities, systems, and equipment in pharmaceuticals, biologics, and medical device manufacturing environments. Santana has developed and taught much of Barry-Wehmiller Design Group’s internal training curriculum for the regulatory compliance practice. Prior to joining Barry-Wehmiller Design Group, Santana worked in pharmaceutical formulation development R&D, process development and engineering, and regulatory compliance for Schering Plough Research Institute and GSK. Santana holds a bachelor of science in applied analytical chemistry from the New Jersey Institute of Technology.

Joonleong Ng
Business Director Singapore
dambrose

Joonleong Ng has 15 years of experience across the APAC region with a focus on commissioning, qualification, and validation in the pharmaceutical industry. Throughout the years, Ng has gathered extensive hands-on and management experience. He also possesses in-depth knowledge of regulation and guidelines, project management, change control process, and lean leadership.

Register Free: https://www.pharmexec.com/pe_w/advancing-validation

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Gen Li
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Gaugarin Oliver
August 1st 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 1st 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Stock.adobe.com
August 1st 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity
August 1st 2025

Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity

Don Tracy, Associate Editor
The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Gaugarin Oliver
August 1st 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 1st 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Stock.adobe.com
August 1st 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity
August 1st 2025

Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity

Don Tracy, Associate Editor
The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.